Search
Emerging stronger, as one
For the healthcare community. For patients. For all.
All of us are striving to navigate the uncertainty of the COVID-19 pandemic. As the current healthcare focus is on delivering patient care, providing rapid and accurate diagnosis and preparing for global vaccination distribution, we are leveraging our expertise and global reach to provide support and continued access to critical healthcare products. With unwavering commitment, we stand united with you—now and into the future.
Download a copy of the BD Statement on COVID-19 (Coronavirus)
Our responsibility in a time of crisis
Supporting the global COVID-19 response
Detection and identification
Products for COVID-19 testing
BD SARS-CoV-2 Reagents
Real-time RT-PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in nasopharyngeal and oropharyngeal swab samples.
BioGX SARS-CoV-2 Reagents
A real-time RT-PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in nasopharyngeal and oropharyngeal swab samples.
BD Veritor™ SARS-CoV-2 Assay
The BD Veritor™ System for Rapid Detection of SARS-CoV-2
Order status, order tracking, delivery confirmation and estimated delivery dates
Order status lookup
COVID-19 blogs
Learn moreBD Statement on COVID-19 (Coronavirus)
Updated November 2020
BD is closely monitoring the COVID-19 (coronavirus) situation across the world and guidance from the U.S. Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO) and health officials in a variety of affected countries to protect the health and safety of BD employees while ensuring continued availability of BD’s critical medical devices at this unprecedented time.
Status of BD operations and supply chain
BD manufactures and sources product from multiple locations around the world. All of our global manufacturing and distribution centers are operational at this time, with the vast majority of critical-to-COVID sites operating at or near full capacity. In countries where local governments have imposed stricter “lockdown” measures to slow the spread of coronavirus, BD’s operations continue to operate with measures in place to ensure business continuity and minimize risk of disruption to our customers.
In addition, BD continues to work closely with our key suppliers around the world that provide raw materials and components to BD manufacturing plants. We have implemented business continuity measures to mitigate the risk of potential supplier disruption, including partnering with local governments to seek “essential business” exemptions for key suppliers where necessary. For the majority of products considered critical-to-COVID, BD continues to have sufficient raw material and component inventory.
BD is making every effort to ensure product is transported to distributors and customers as quickly and efficiently as possible. We are actively monitoring our global logistics and transportation network, taking necessary actions to work around global capacity and border constraints to minimize the risk of any customer delays.
We are continuing to enforce our pandemic protocols and measures within our facilities to maintain the health and safety of our associates while ensuring business continuity for our customers.
Product availability
Across BD, we are closely monitoring inventory and customer ordering to ensure supply continuity. For U.S. customers, an up-to-date list of products on manual inventory allocation can be found at bd.com/allocation.
Business continuity planning
BD has business continuity plans for these types of situations. If a product or raw material is deemed at risk, BD will adopt numerous contingency plans including seeking alternative suppliers, expediting shipments, redeploying raw materials and/or finished goods from other parts of the BD network and placing at-risk products on order review to prevent hoarding behavior. BD also institutes preventative pandemic precautions at facilities to protect employees, including increasing cleaning protocols, implementing temperature screenings for on-site employees, deploying PPE to on-site employees and field workers, implementing social distancing controls in our facilities, supporting work-from-home for all employees who are able, suspending travel and group meetings, limiting on-site visitors, and regularly educating employees about good hygiene and health practices, including social distancing, self-quarantining and handwashing.
Supporting global response
As one of the largest global medical technology companies in the world, BD is deploying our capabilities, expertise and scale to address critical health needs related to coronavirus – from our diagnostic offerings to detect SARS-CoV-2, to real-time informatics and electronic surveillance technology, to essential medical devices to support patient care. Specifically, BD:
- Is leveraging its global manufacturing network and scale to produce 8 million SARS-CoV-2 antigen tests per month and expects to produce 12 million tests per month by March 2021.
- Committed more than 800 million injection devices to date to governments and multi-lateral organizations around the world in support of COVID-19 vaccination campaigns, with discussions underway to provide millions more devices.
- Announced multiple new products to help aid in the detection and identification of COVID-19, including a molecular test for the detection of COVID-19 for clinical laboratories in countries recognizing the CE mark.
- Received FDA Emergency Use Authorization (EUA) and EU CE mark; and launched a portable, rapid point-of-care antigen test to detect SARS-CoV-2 in 15 minutes, dramatically expanding access to SARS-CoV-2 testing.
- Received CE mark and Emergency Use Authorization (EUA) from the FDA for an additional molecular diagnostics test for COVID-19 that can return results in two to three hours, helping to increase the availability of tests around the world.
- Partnered with BioGX to launch a new diagnostic test that will enable hospitals to screen for COVID-19 on site and get results in under three hours.
- Partnered with CerTest Biotec and received CE mark for combination SARS-CoV-2, Influenza, RSV test on the BD MAX™ Molecular Diagnostic System.
- Is collaborating with peers from across the industry, HHS, FDA and private partners to identify and validate additional swab types as well as transport medium options in order to expand capacity and alternative collection methods.
- Announced the launch of the Prevention Course in HAI Knowledge and Control, developed independently by the Society for Healthcare Epidemiology of America (SHEA) and supported in full by an educational grant from BD.
In addition, BD and the BD Foundation have issued nearly $2.5 million in philanthropic grants and product donations to trusted non-profit partners that are working to protect the most vulnerable communities and individuals from the pandemic’s spread and negative impacts. BD volunteers are heeding the call, too. Clinically trained associates in sites around the world are volunteering their time to augment hospital staff in communities hard-hit by COVID-19; and associates from a broad range of disciplines are delivering virtual trainings to teach community and non-profit organizations how to contain its spread.
For more on BD’s response efforts, visit our video library.
Contact Support